{"description":"Adverse event and/or serious adverse event recorded according to targeted reporting outlined in protocol.\n\n1. Events requiring prompt reporting including, but not limited to unanticipated death of a locally enrolled subject(s); new or increased risk; any adverse event that require a change to the protocol or consent form or any protocol deviation that resulting in harm\n2. graft failure by Day 42 post-transplant","eventGroups":[{"deathsNumAffected":1,"deathsNumAtRisk":5,"description":"Hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycles of multi-agent chemotherapy within the 3 months previous to umbilical cord blood transplantation.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":5,"seriousNumAffected":0,"seriousNumAtRisk":5,"title":"No Anti-thymocyte Globulin (ATG)"},{"deathsNumAffected":2,"deathsNumAtRisk":10,"description":"Hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplantation, should receive Anti-thymocyte Globulin (ATG) as part of their conditioning regimen.","id":"EG001","otherNumAffected":0,"otherNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"title":"Anti-thymocyte Globulin (ATG)"}],"frequencyThreshold":"5","timeFrame":"6 months"}